Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2017 12:10 ET | Source: Immunomedics, Inc.

Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC)

Objective Response Rate (ORR) = 31% (Centrally Reviewed); 34% (Locally Assessed) Median Duration of Response (DOR) = 9.1 Months (Centrally Reviewed); 7.6 Months (Locally Assessed) Clinical Benefit...
November 13, 2017 09:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium

MORRIS PLAINS, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that two of its abstracts were posted online at...
November 09, 2017 16:10 ET | Source: Immunomedics, Inc.

Immunomedics Announces First Quarter Fiscal 2018 Results and Provides Corporate Update

Announces Appointments of Michael Pehl as President and Chief Executive Officer and Brendan Delaney as Chief Commercial Officer Late-breaker Abstract on Updated Phase 2 Results of IMMU-132 in...
November 09, 2017 16:05 ET | Source: Immunomedics, Inc.

Immunomedics Appoints Michael Pehl President and Chief Executive Officer to Lead Next Phase of Transformative Growth

MORRIS PLAINS, N.J., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that its Board of Directors has voted to appoint Michael...
November 02, 2017 08:00 ET | Source: Immunomedics, Inc.

Immunomedics to Report First Quarter Fiscal 2018 Results and Host Conference Call and Webcast on November 9, 2017

MORRIS PLAINS, N.J., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it will host a conference call on Thursday, November 9,...
September 15, 2017 08:00 ET | Source: Immunomedics

Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock

MORRIS PLAINS, N.J., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that it has entered into privately negotiated exchange...
September 11, 2017 07:00 ET | Source: Immunomedics

Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer

Confirmed Objective Response Rate (ORR) of 34%, Two Confirmed Complete Responses (CRs) and Twelve Confirmed Partial Responses (PRs) Median Duration of Response (DOR) of 12.6 Months Median...
August 30, 2017 08:00 ET | Source: Immunomedics

Immunomedics to Participate in Upcoming Investor Conferences

MORRIS PLAINS, N.J., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that the Company will present an overview of its business at...
August 21, 2017 08:00 ET | Source: Immunomedics

Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer

MORRIS PLAINS, N.J., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today announced that labetuzumab govitecan (IMMU-130), the second agent from...
August 16, 2017 16:00 ET | Source: Immunomedics

Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline

MORRIS PLAINS, N.J., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ:IMMU) (“Immunomedics” or the “Company”) today reported financial results for the fourth quarter and fiscal year...